fda warning letters glp-1 september 2025 issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA takes aim at telehealth

A study of stage 3 DKD patients showed that canagliflozin 100 and 300 mg were associated with greater decreases in urine albumincreatinine ratio (UACR) compared with placebo [31]

Quick Picks by Your Need Heres the single best provider for each common need

Patients starting semaglutide or other GLP-1 therapies should continue monitoring their lipid panels with their primary care physician, as baseline medications may require adjustment based on changing cholesterol levels

Instead of just describing a feeling, you can show them a professionally interpreted ECG report, turning your wearable from a gadget into a proactive health tool

Differentiating Multiple Sclerosis from Myalgic Encephalomyelitis and Chronic Fatigue Syndrome

: